These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15683598)

  • 1. Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease risk.
    Nambi V; Ballantyne CM
    Curr Atheroscler Rep; 2005 Feb; 7(1):22-8. PubMed ID: 15683598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
    Albert MA; Staggers J; Chew P; Ridker PM;
    Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-reactive protein levels and outcomes after statin therapy.
    Ridker PM; Cannon CP; Morrow D; Rifai N; Rose LM; McCabe CH; Pfeffer MA; Braunwald E;
    N Engl J Med; 2005 Jan; 352(1):20-8. PubMed ID: 15635109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory markers in coronary heart disease.
    Madjid M; Willerson JT
    Br Med Bull; 2011; 100():23-38. PubMed ID: 22010105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of C-reactive protein on treatment of patients with cardiovascular disease.
    Gortney JS; Sanders RM
    Am J Health Syst Pharm; 2007 Oct; 64(19):2009-16. PubMed ID: 17893410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease.
    Rifai N; Ridker PM
    Clin Chem; 2001 Mar; 47(3):403-11. PubMed ID: 11238289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
    Ridker PM; Rifai N; Clearfield M; Downs JR; Weis SE; Miles JS; Gotto AM;
    N Engl J Med; 2001 Jun; 344(26):1959-65. PubMed ID: 11430324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
    Bays HE; Davidson M; Jones MR; Abby SL
    Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
    Koenig W
    Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease.
    Horne BD; Muhlestein JB; Carlquist JF; Bair TL; Madsen TE; Hart NI; Anderson JL
    J Am Coll Cardiol; 2000 Nov; 36(6):1774-80. PubMed ID: 11092643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
    J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of plaque echolucency in combination with inflammatory biomarkers on cardiovascular outcomes of coronary artery disease patients receiving optimal medical therapy.
    Ishizu T; Seo Y; Machino T; Kawamura R; Kimura T; Murakoshi N; Sato A; Takeyasu N; Watanabe S; Aonuma K
    Atherosclerosis; 2011 May; 216(1):120-4. PubMed ID: 21353222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease.
    Horne BD; Muhlestein JB; Carlquist JF; Bair TL; Madsen TE; Hart NI; Anderson JL;
    Circulation; 2003 Jan; 107(2):258-63. PubMed ID: 12538425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
    Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
    Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using statins to treat inflammation in acute coronary syndromes: Are we there yet?
    Shishehbor MH; Patel T; Bhatt DL
    Cleve Clin J Med; 2006 Aug; 73(8):760-6. PubMed ID: 16913201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.